Guggenheim Raises Apogee Therapeutics PT to $160, Maintains Buy Rating

martes, 24 de marzo de 2026, 7:47 am ET1 min de lectura
APGE--

Guggenheim Raises Apogee Therapeutics PT to $160, Maintains Buy Rating

Guggenheim Raises Apogee Therapeutics PT to $160, Maintains Buy Rating

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios